Literature DB >> 17825481

Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth.

David G DeNardo1, Valerie L Cuba, HeeTae Kim, Kendall Wu, Adrian V Lee, Powel H Brown.   

Abstract

In this study, we determined whether ER DNA binding is necessary for estrogen to stimulate the growth of breast cancer cells. To investigate the requirement of ER DNA binding we expressed either wild-type or a DNA-binding mutant ERalpha in a clone of the MCF-7 breast cancer cell line that no longer expressed endogenous ERalpha. Estrogen did not activate non-genomic kinase cascades in the parental MCF-7 cells or in cells expressing ERalpha mutant. In cells expressing the ERalpha mutant, estrogen did not induce ERE-dependent gene expression but did induce AP-1- and Sp1-dependent gene expression and the cell cycle regulatory genes cyclin D1 and c-myc. However, we demonstrated that estrogen still induced cell proliferation in MCF-7 cells expressing the ERalpha mutant. These results demonstrate that ER DNA binding is not absolutely required for estrogen to induce breast cancer cell growth.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17825481     DOI: 10.1016/j.mce.2007.07.006

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  22 in total

1.  Distinct transcriptional regulation of human large conductance voltage- and calcium-activated K+ channel gene (hSlo1) by activated estrogen receptor alpha and c-Src tyrosine kinase.

Authors:  Shahab M Danesh; Pallob Kundu; Rong Lu; Enrico Stefani; Ligia Toro
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

Review 2.  Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.

Authors:  Todd W Miller; Justin M Balko; Carlos L Arteaga
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

Review 3.  HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.

Authors:  Frank E Jones
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-13       Impact factor: 2.673

Review 4.  Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma.

Authors:  L G Estévez; E García; M Hidalgo
Journal:  Clin Transl Oncol       Date:  2015-10-28       Impact factor: 3.405

Review 5.  Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.

Authors:  Xiaoyong Fu; C Kent Osborne; Rachel Schiff
Journal:  Breast       Date:  2013-09-05       Impact factor: 4.380

6.  Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-α36 (ERα36).

Authors:  Reyhaan A Chaudhri; Rene Olivares-Navarrete; Natalia Cuenca; Agreen Hadadi; Barbara D Boyan; Zvi Schwartz
Journal:  J Biol Chem       Date:  2012-01-13       Impact factor: 5.157

7.  Cadmium promotes breast cancer cell proliferation by potentiating the interaction between ERalpha and c-Jun.

Authors:  Christina L Siewit; Bridget Gengler; Esera Vegas; Rachel Puckett; Maggie C Louie
Journal:  Mol Endocrinol       Date:  2010-03-10

8.  Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.

Authors:  Tracy E Strecker; Qiang Shen; Yun Zhang; Jamal L Hill; Yuxin Li; Chunyu Wang; Hee-Tae Kim; Tona M Gilmer; Krystal R Sexton; Susan G Hilsenbeck; C Kent Osborne; Powel H Brown
Journal:  J Natl Cancer Inst       Date:  2009-01-13       Impact factor: 13.506

9.  Genomic responses from the estrogen-responsive element-dependent signaling pathway mediated by estrogen receptor alpha are required to elicit cellular alterations.

Authors:  Stephanie L Nott; Yanfang Huang; Xiaodong Li; Brian R Fluharty; Xing Qiu; Wade V Welshons; Shuyuan Yeh; Mesut Muyan
Journal:  J Biol Chem       Date:  2009-03-24       Impact factor: 5.157

10.  Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.

Authors:  G L Powers; S J Ellison-Zelski; A J Casa; A V Lee; E T Alarid
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.